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Colorectal cancer (CRC) is one of the leading causes of death by cancer in New Zealand, 
largely due to metastasis of the primary tumour to secondary sites around the body. The 
initiation, progression and eventual metastasis has been shown to be largely influenced by 
epimutations. DNA methylation is a stable, heritable epigenetic mark which has been heavily 
implicated in disease. In cancer contexts, global hypomethylation and focal hypermethylation 
act to grossly dysregulate the genome, while simultaneously acting as potential biomarkers for 
initial detection and therapeutic response.  
 
CRC is a molecularly heterogeneous disease, including between patients, tumours and even 
within the tumours. As well as this, tumours are comprised of immune cells, healthy tissue cells 
and blood cells in tandem with the neoplastic cells. Traditionally, these populations are 
sequenced as a whole. Consequently, the methylomes of each cell are coalesced, giving rise to 
averaged methylation profiles. The emergence of single cell technologies allows us 
deconvolute heterogeneous populations of cells and identify different cell states and types. 
 
Obtaining high quality data from a single cell is difficult due to the minimal amount of starting 
DNA, particularly in single-cell bisulfite sequencing as the bisulfite conversion is harsh on the 
DNA. Hence, the main aim of this project was to optimise and implement single-cell bisulfite 
sequencing on a sorted human colorectal cancer cell line. Following this, my second aim was 
to compare the methylation profiles of the single-cell methylation libraries to uncover 
heterogeneity in the population. In this project, I use a post-bisulfite adaptor tagging (PBAT) 
method to perform single cell bisulfite sequencing on the CRC human cell line HT29. 
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Following this, I use a publicly available data set to investigate intra- and inter- tumour 
heterogeneity.  
 
With a few optimization steps the PBAT method was able to successfully amplify very small 
numbers of cells, including 100, 10, 5 and two single cell samples. Following this, publicly 
available data showed even in a small population of single cells, there was evident 
heterogeneity regarding global, chromosomal and focal promoter methylation.  
 
These results highlighted the heterogeneity which can be unmasked using single cell 
technologies, even on a small scale. While also confirming renowned biological models such 
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Chapter 1: Introduction 
Many of our current biological models are based on the bulk sequencing of heterogeneous 
cell populations, yet they may not hold true when scrutinised at a single cell level. This 
project aimed to carry out a single cell bisulfite sequencing (scBS-seq) method on colorectal 
cancer (CRC) cells to elucidate the heterogeneity surrounding the disease. The following 
sections of this chapter introduce key concepts in understanding single cell bisulfite 
sequencing, including techniques and limitations associated with it. Moreover, it details the 
implications of this new technology on studying the molecularly heterogeneous disease, 
colorectal cancer.   
  
1.1 DNA Methylation  
Epigenetics; once described as “the most obvious source of dark matter” [4] in the cancer 
genome – now an exceedingly researched area providing answers to long-asked questions. 
Epigenetics is described as “the study of changes in gene function that are mitotically and/or 
meiotically heritable and that do not entail a change in DNA sequence.” [5]. One of the main 
epigenetic alterations is DNA methylation (DNAme), a stable yet reversible mark entailing 
the addition of a methyl group typically at the 5th position of a cytosine residue adjacent to a 
guanine residue (CpG site), or sometimes at non-CpG sites (CpH, H = A, C or T). DNAme is 
involved in many fundamental biological processes throughout the entire life span, including 
cell-cycle control, cell-fate decisions, X chromosome inactivation [6], genomic imprinting 
[7], embryonic development, chromosomal stability and transposable element silencing [8]. 
Many - if not all - of these processes when aberrantly regulated have been implicated in a 
number of diseases, including heart disease [9], autoimmune diseases [10] and diabetes [11]. 
Of particular interest to my project, is its role in CRC [12]. Epigenetics is an area of extensive 
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research particularly in development and disease, as a result of its influence on gene 
expression as well as susceptibility to external factors.  
 
1.1.1 DNA Methylation Dogma 
The most widely accepted dogma for DNAme in gene regulation is that it acts to silence 
genes. It is thought that its presence either acts to recruit repressive transcription factors or 
physically block any activating transcription factors or RNA polymerase from binding to the 
promoter [13, 14]. However, when present in a gene body context rather than a gene 
promoter, it has been linked to transcriptional elongation and alternative splicing [15]. A 
number of studies have now emerged which display hypermethylation-induced 
transcriptional activation, not only in disease but in normal developmental processes [16]. 
This has been shown in melanoma, where the methylation of the EBF3 promoter is associated 
with an increase of gene expression [17, 18]. Another recent study also found 
hypermethylation in several genes in prostate cancer patients were associated with 
upregulation, suggesting its presence in some contexts may act to increase gene expression 
[19]. This highlights the diverse and not yet fully understood means in which DNAme acts to 
regulate gene expression. Not to mention, the diverse role DNAme also plays in maintaining 
structural integrity of the genome [20]. 
 
1.2 Single Cell DNA Methylation  
Historically, due to technical limitations bulk populations of tissue samples have been 
analysed for methylome data. Bulk analysis refers to a large population of cells being 
coalesced followed by sequencing, resulting in an averaged methylome profile. The past few 
years have seen the emergence of single-cell technologies allowing for the analysis of 
epigenomes of single cells. A popular analogy when comparing bulk sequencing to single cell 
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sequencing is the “fruit salad/smoothie” analogy. Bulk sequencing is synonymous to a fruit 
smoothie – in that all the different fruits are blended, and an averaged taste profile of all fruits 
is produced. Single cell sequencing is synonymous to a fruit salad – you eat each bit of fruit 
individually and only get that fruits taste profile, without being tainted by any other flavour. 
To refer this back to methylomes, bulk sequencing is combining a myriad of cells that contain 
differing methylomes, resulting in averaged data. Single cell sequencing will only provide the 
methylome of that single cell, allowing for the characterization of rare sub-populations of 
cells and provides insight into the genetic regulation of heterogeneous populations of cells. 
 
The ability to deconvolute heterogeneous populations of cells and identify different cell states 
and types is engaging particularly in cancer contexts.  
 
1.2.1 Single Cell Sequencing Techniques 
The recent ability to study cells at the singular level has come from new technology enabling 
the isolation of single cells from a population. This, along with improved amplification steps 
and growing bioinformatic tools.  
 
The first step to these analyses is the isolation of the single cells from their population. In the 
earlier stages, fluorescence-activated cell sorting (FACS), laser-capture microdissection 
(LCM) and micromanipulation were used to physically isolate single cells, usually only tens 
to hundreds at a time [21]. More recently, separating the cells into droplets via a unique 
barcode which has been tagged to specific sequence reads of a cell has allowed for the 
isolation of thousands of cells rather than hundreds [22]. Following this, they can be pooled 
back together and reactions such as bisulfite conversion can be done on a bulk population, 
dramatically reducing costs and increasing sensitivity [23]. Of interest to this project, FACS 
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live-dead staining was used to sort cells. This entails using a FVS450 dye which stains cells 
with permeable membranes. In essence, non-viable/dead cells will have a high fluorescence 
as a result of higher dye uptake, whereas viable/live cells will take up less dye resulting in a 
lower fluorescence for sorting. This method was used for my project as I did not need to 
select for any certain cell type, as all cells were HT29 my selection was for live cells [21].  
 
Once the cells have been isolated, several DNAme analyses can be employed dependant on 
the research (Table 1). The method used in my project; single cell bisulfite sequencing (scBS-
seq) is a single base resolution technique. This is a gold-standard method for whole genome 
methylation analyses and studies wishing to get high-resolution data [24]. Despite this, it 
tends to be biased towards CpG rich genomic regions, have a relatively high cost and there is 
substantial DNA degradation during the bisulfite conversion process. This method was 
adapted to single cells to minimize adaptor-tagged fragment degradation through post-
bisulfite adaptor tagging, in which the bisulfite conversion is performed before the adaptor 
tagging in library amplification rather than after as is done in bulk sequencing.  Single cell 
methylation sensitive restriction enzyme sequencing (scMSRE) is another technique, in 
which an enzyme will cut at specific unmethylated cytosine residues, unable to cut 5mC 
residues. scMSRE is of greater time and cost efficiency than bisulfite methods yet do not 
have whole genome coverage. However, scMSRE results in less DNA degradation, making it 
suitable for site-specific or targeted studies. The last common method of note is single cell 
reduced representation bisulfite sequencing (scRRBS), a combination of enzyme restriction 
techniques and bisulfite techniques. scRRBS is more cost effective yet has less coverage than 
scBS-seq. scRRBS is also biased in regions with high CpG density and has low coverage in 
low CpG dense regions. These techniques have been summarized in table 1. Due to wanting 
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to investigate the methylome of my cells, the most appropriate technique for my project was 
the scBS-seq technique described above.  
 
Table 1. Single cell methylome sequencing techniques. Adapted from Kashima et al. 
2020.  
 
The above methods are common for single cell DNAme analyses; however, an increasingly 
popular single cell technique is the multi-omics method. This method integrates proteome, 
genomes, epigenomes and transcriptomes from the same cell to give a comprehensive insight 
into how the omics are all interrelated [29, 30]. This allows for the parallel profiling of multi-
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layers in single cells to identify causal relationships between epigenome regulation and gene 
expression. This is a favourable technique as lack of methylation does not always infer gene 
expression and vice versa.  
 
1.3 Epigenetics of Colorectal Cancer  
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in New 
Zealand, with New Zealand having one of the highest CRC incidences in the world [31]. This 
incidence has significantly increased in the past few decades, which can in part be attributed 
to an ageing population, unhealthy modern diets and increased risk factors such as smoking, 
alcohol consumption and obesity [32]. As described earlier, these environmental influences 
have a large effect on our epigenomes. Currently, the most effective strategy against CRC 
mortality is early screening. When CRC is detected in early stages while it is still confined to 
the bowel wall, surgical cure rates are above 75% [33]. However, this rate drops significantly 
once the primary tumour has metastasised.  
 
CRC is a highly molecularly heterogeneous disease [34]. Heterogeneity refers to the 
observation that individual tumour cells will present with distinct morphological and 
phenotypic profiles. Heterogeneity can be seen within a tumour (intra-tumour), between the 
primary tumour and its metastases (inter-tumour) and between individuals (inter-individual) 
[34]. The heterogeneous nature of CRC means patients will often have varied responses to 
treatment alongside varied prognoses [35].  
 
Collectively, the genome and epigenome of cancer cells are grossly dysregulated. 
Exploitation of pathways required in normal biological processes results in the initiation, 
progression, dissemination and metastases of cancer [14, 36]. A common feature of the 
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cancer epigenome is global DNA hypomethylation [37-39]. This is an early event often 
observed in early neoplastic lesions of the colon [40]. DNA global hypomethylation refers to 
an overall drop in the level of methylation observed across the cancer genome of neoplastic 
cells compared to adjacent healthy tissues. This DNA global hypomethylation contributes to 
the dysregulated cancer genome in a number of ways. Often, this state reflects a decrease in 
methylation of DNA repeat elements, which recent studies suspect makes up as high as two-
thirds of the human genome [41]. The loss of methylation at these typically silenced repeat 
elements can lead to transposition, chromatin rearrangement and genomic instability 
contributing to the cancer genome [42].  
 
Moreover, focal hypermethylation in promoters of tumour suppressor genes is another 
frequented epigenetic event in CRC [43-45]. Through silencing of promoter/enhancer regions 
or long-regulatory distal elements, genes often involved in cell cycle regulation, DNA repair, 
apoptosis, angiogenesis, invasion and adhesion can become silenced [46]. On account of this 
silencing, further genomic instability can also be imposed. Famously, the MLH1 gene 
involved in DNA mismatch repair (MMR) is frequently silenced in CRC patients with a high 
microsatellite instability (MSI) phenotype [44]. Another deeply explored gene is CDH1, the 
gene for the E-cadherin protein [47, 48]. CDH1 is often hypermethylated in CRC, in order to 
facilitate the dissemination of cells from the primary tumour and subsequent metastasis to 
new locations in the patient’s body [47]. On account of this silencing, further genomic 
instability can also be imposed.  
 
On the contrary, instances of focal hypomethylation have also been observed in CRC 
contexts [49]. Focal promoter hypomethylation has been reported in what is known as 
oncogenes. Oncogenes, when overexpressed, often contribute to cellular proliferation, 
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metastasis and invasion [49]. For example, CD276 has been shown to be frequently 
hypomethylated and subsequently contribute to tumour progression and chemosensitivity 
through regulating oncogenic signalling pathways [50]. CD276 also contributes to tumour 
cell evasion of the immune system [51]. Loss of methylation at imprinted genes in the 
genome has also been reported, most commonly explored in CRC being the insulin-like 
growth factor 2 (IGF2) [52]. The loss of imprinting (LOI) means both parental alleles are 
now expressed, not just one. In the case of IGF2, it’s overexpression leads to activation of 
downstream genes which are powerful cellular proliferators [52].   
 
DNAme, although commonly associated with the silencing of genes, plays an expansive role 
across the genome. The presence of DNAme does not always infer silencing of gene 
expression, it also controls telomere length and recombination, chromatin structure and 
silencing repeat elements [53]. Understanding the complex interactions that act to regulate 
the cancer genome is essential when analysing not only SCS data, but bulk also. 
 
The distinct methylation phenotypes described above can yield clinically useful biomarkers 
for the detection of CRC as well as prognostic/therapeutic predictions [54]. In the following 
section, I will detail how the introduction of SCS in exploring the outlined mechanisms can 
contribute clinically and theoretically to our understanding of CRC.  
 
1.3.1 Single Cell Methylome Sequencing in Colorectal Cancer  
The emergence of single cell bisulfite sequencing in the CRC research field is valuable, when 
considering the heterogeneity of the disease and the influence of DNAme on the cancer 
genome as described above. The following section will detail areas of research in CRC which 








The first mechanism that would benefit from the use of scBS-seq is analysing circulating 
tumour cells (CTCs). CTCs are capable of detaching from the primary tumour, surviving in 
the blood stream and eventually colonising a new environment in the body [55]. Studies have 
shown DNAme heavily influences the ability of a CTC to metastasise through influencing 
EMT genes as well as stem cell-like genes [56]. On account of this, scrutinising the 
methylome of CTCs is an essential component to understanding the epigenetic factors which 
favour these cells over others in the tumour to metastasise. Analysing CTCs has been difficult 
previously, due to the low DNA content. Using scBS-seq to analyse CTCs has the potential to 
provide insight into the epigenetic processes that may drive the metastatic cascade of CRC 
cells and subsequent invasion at new locations, as well as introduce new biomarkers. 
Figure 1 | Schematics of possible applications of single cell bisulfite sequencing in colorectal cancer 
contexts. Applications include sequencing circulating tumour cells, personalising patient treatment, 
investigating mechanisms of metastasis, elucidating intra-tumour heterogeneity, investigating inter-
individual heterogeneity, and sequencing rare cancer stem cells. CTCs = circulating tumour cells, ITH = 
intra-tumour heterogeneity, CSCs = cancer stem cells. Figure made using biorender.com. 
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Additionally, due to CTCs being found in the blood, being able to extract these cells from 
blood drawing is far less invasive than other methods such as biopsies. Also of note, one 
study found that there was a substantial amount of methylome heterogeneity amongst distinct 
CTCs from the same patients [57]. This could lead to personalised signatures in these CTCs 
for patient stratification and treatment selection. In essence, scBS-seq allows for investigation 
of new potential biomarkers and identification of these in patients CTCs.  
 
Other applications of scBS-seq in a CRC context is investigating intra-tumour heterogeneity. 
Tumours in CRC patients are comprised of a number of different cells within the tumour, 
including the malignant and healthy cells from the bowel, fibroblasts, immune cells and 
nerves [58]. Prior to SCS, these cells were all sequenced as a whole, disregarding the distinct 
methylomes that each of these cells would have. Not to mention, the variation of methylomes 
observed between tumour cells alone is substantial, let alone including methylomes of 
healthy cells to further mask any differential areas. Single-cell sequencing provides a tool for 
understanding the complex heterogeneity that encompasses each individual tumour. Such 
information will not only augment our current understanding on the CRC methylome but 
provide clinical insights such as responsiveness to therapy, patient prognoses and disease 
relapse.  
 
Another branch of cancer research that SCS allows further investigation into is cellular 
lineage. Understanding lineage can inform on the cancer cell-of-origin, working to 
characterize and identify when the tumorigenic transformation occurred [59]. It can also trace 
lineages of cancer stem cells (CSC), a small number of cells thought to be capable to self-
renewal, differentiation and tumorigenicity [60]. It is thought CSC’s are resistant to 
chemotherapy and radiation, a potential cause of metastasis and even initiation of the primary 
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tumour [61]. As mentioned earlier, metastasis of CRC significantly decreases a patient’s 
chance of recovery, and therefore exploring small subpopulations such as CSCs is a vital task 
which can now be done at higher precision with SCS. Without scBS-seq, CSCs which are 
likely to have methylomes which diverge from normal neoplastic cells would be hidden as 
majority of the tumour is not composed of CSCs.  
 
The concept of heterogeneity is of notable importance in the context of therapy, as it only 
requires one cell to be non-responsive to the therapy to result in a relapse, or in some cases no 
response at all. For example, it was found glioblastoma patients who had methylated MGMT 
promoters were more responsive to alkylating agents for treatment as opposed to those 
without this methylation [62]. One study also showed that different epigenomic 
subpopulations varied in their response to targeted therapy, with one subpopulation showing 
greater resistance to imatinib [63]. Using scBS-seq to identify any cells with methylation 
biomarkers which may be indicative of resistance to certain therapies could inform 
oncologists on which treatments should be combined for the most effective treatment; a form 
of personalised treatment. Furthermore, using scBS-seq to monitor the progress of treatment 
and any potential arising drug-resistant subpopulations through epigenetic biomarkers could 
be used to direct future steps for therapy. Prior to SCS, these small drug-resistant populations 
would have had their biomarkers masked by the averaged profile of all the other tumours 
cells. Of course, methylome sequencing is not yet a frequently used tool in clinical practice, 
hence the above arguments are merely suggestions of what could be achieved in future if it 
were to become common practice.  
 
The use of single cell techniques has been popularly used in single cell RNA analyses of 
cancer rather than methylome analyses. The number of papers available on RNA single cell 
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analyses yields upwards of 8,000 PubMed search results in the past 5 years, comparatively 
single cell DNAme analysis papers yield less than 300 PubMed search results. This is likely 
in part due to the difficulty of DNAme analyses. Single cell DNAme only utilises the double 
stranded DNA in the single cell, whereas there is a lot more RNA present in a single cell. As 
well as this, the process of amplification is much easier on the RNA than on the DNA during 
methylation. mRNA is converted to cDNA via reverse transcriptase and subsequently 
amplified, whereas DNAme analyses require manipulation of the native DNA [64]. As a 
result of this, there is still a limited amount of research done on single cell methylomes, even 
less so in a cancer context. The currently available papers which used single cell methylome 
sequencing in the context of cancer have been summarised in table 2. Nonetheless, the 
epigenetic influence on CRC and its inherent heterogeneity makes single cell DNAme 

















   
















2016 Hou, Guo [65] 
Metastatic breast 
cancer (mBC) and 
metastatic 















at these promoters in 














identified in patients 
found metastases at 
multiple sites had a 
common origin. 















expelled from lymph 
























CTCs based on 
methylomes. 
2021 Chen, Su 
[68] 
 
Table 2. Examples of single cell methylome analyses in cancer. Adapted 
from Karemaker and Vermeulen [2]. 
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1.4 Challenges in Single Cell DNA Methylation   
The ability to sequence individual cells to uncover cellular heterogeneity at a mono- or multi-
modal level is a big jump in the field, yet not without its challenges. There tends to be 
coverage non-uniformity, sparse data, false-positives, amplification biases and allelic drop 
out events [69]. 
 
As mentioned earlier, the popularity of scRNA-seq has resulted in a number of bioinformatic 
tools to aide in making inferences from single cell data. Clustering methods for cell 
population characterization [70-72] as well as network inference tools [73, 74] have been 
developed for scRNA-seq techniques. Comparatively, the lack of studies done thus far in 
scBS-seq is reflected in the lack of bioinformatic tools. In addition, there are no clear 
DNAme cell type markers as there are transcriptomic cell type markers, making clustering 
more difficult. 
 
High-throughput single cell DNAme studies have CpG coverage of around 5% [75], while 
low throughput studies have around 20% [76] genome-wide CpG coverage. This makes it 
relatively difficult to distinguish cells from one another with large gaps, or to infer the 
epigenetic control mechanisms of that cell with very sparse coverage. The analysis tool 
MELISA (MEthyLation Inference for Single cell Analysis) has been created to alleviate these 
issues. MELISA predicts methylation status of missed CpGs based on information from 
neighbouring CpGs and from other cells with similar methylation patterns [77]. Although, it 
must be considered that through using predictive statistical models such as MELISA, the 
methylation status may be incorrectly predicted and therefore lose a differently methylated 




As expected, when sequencing a minute amount of DNA, the technical noise is very high. 
The scarce coverage of processed single cell epigenome data requires appropriate 
normalization of data and these high levels of noise need to be accounted for. Single cell 
transcriptomics have spike-in standards to control for technical noise, yet strong 
normalisation strategies have not yet been established for epigenome sequencing. One study 
combined approximately 100 single cells to identify peaks via algorithms already in place for 
bulk sequencing, then looked at each cell to see if these peaks were present [78]. This 
aggregation method however cannot account for cells with specific loci exhibiting low levels 
of DNAme. A number of methods have also been formed through comparing regions which 
have similar methylation levels in cis-regulatory elements through ENCODE [79]. Another 
challenge with this small amount of DNA is the bisulfite conversion process. It is a harsh 
reaction on a very small amount of DNA, leading to substantial degradation. Although 
methods have been adapted to account for this, it still remains a challenge. 
 
The potential for contamination throughout the process of single cell DNA methylation is 
also very high and may skew results. Any DNA that contaminates samples early on will be 
amplified with the cellular DNA and may provide false results. Also, the multiple rounds of 
amplifications required means addition of reagents may lead to further contamination. 
Negative controls at multiple time points such as before treatment, after and throughout 
amplification may help to alleviate these issues.  
 
Another consideration when analysing SCS data is the target resolution level. This refers to 
grouping the single cells into different organs, different cell types or up to each single cell at 
intermediate cell states. Appropriate analysis tools and reference systems such as cell atlases 
need to be used to reach different levels of resolution. Dependant on the research question, 
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higher resolution may be more insightful, yet increased resolution tends to coincide with a 
decrease in stability of supporting signals. For example, when researching the EMT process 
in metastatic tumour cells, a high resolution including intermediate cell states would be most 
appropriate as the intermediate states influence the phenotype and invasive/migratory 
properties of the cell as described earlier.  
 
Another context which provides new challenges is clinical implementation. Theoretically, the 
use of SCS in a clinical context particularly in targeted therapy for cancer patients seems 
promising. However, more cost and time efficient methods need to be developed which can 
be easily utilised in clinics. This includes cell preparation and streamlined data analysis 
pipelines, where only DNAme levels at loci relevant to the clinical phenotype are shown. 
However, all emerging technologies initially have a high cost, but eventually become very 
affordable. The cost of single-cell transcriptomic assays has already fallen considerably [80], 
and it is likely single cell epigenomics will follow. 
 
The level of technical variability associated with single cell methylation should always be 
considered when drawing conclusions from sc-BS sequencing data.  
 
1.5 Research Aims 
The aim of this project was to implement and optimise a single cell bisulfite sequencing 
protocol on a human sorted colorectal cancer cell line, HT29. The second aim of this project 
upon completion of the first aim, was to bioinformatically analyse the scBS-seq libraries of 
the HT29 cells and investigate the DNAme heterogeneity in the population. Due to COVID-
19 restrictions, the second aim was altered. My second aim was then to analyse a publicly 
available CRC DNAme dataset to examine it for DNAme heterogeneity between cells. I 
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hypothesised that DNAme heterogeneity amongst the population would be apparent 


























Chapter 2: Materials and Methods 
2.1 Cell Culture  
HT29 cells were initiated from liquid nitrogen storage and thawed at 37oc. Cells were kept in 
DMEM + FBS + Penicillin/streptomycin (10% FBS and 1% PS). HT29 is a tumorigenic 
colorectal cancer cell lines with epithelial morphology. HT29 cells were obtained from the 
ATCC.  
 
Cell media was changed every 1-2 days. If cells were >80% confluent, cells were split by 
washing with PBS, trypsinisation for 3 minutes at 37oc, then spun down in falcon tubes 
containing media. Following this, supernatant was replaced with fresh media and transferred 
to a new flask. There were 2 passages after thawing of cells before cells were sorted, meaning 




2.2 Preparation of HT29 Cells for FACS 
FVS450 stain was used for live-dead single cell sorting. 3 tubes were prepared for sorting. 
Tube 1 was an unstained control. Tube 2 contained heat killed cells as a FVS450 control. 
Tube 3 contained FVS450 stained cells for sorting. Cells were harvested via trypsination and 
spun down at 350g for 5 minutes. Cells were resuspended in PBS and diluted to 
approximately 300,000 cells per tube in a 500l volume. Tube 2 cells were heat killed at 
100oc for 5 minutes on a stirrer plate. 1.5l of FVS450 viability dye was added to 1.5ml of 
PBS to make the viability mastermix. 500l of this viability mastermix was added to tube 2 
(heat killed cells) and tube 3 (cells for sorting). 500l of PBS-BSA was added to tube 1, as an 
unstained control. All tubes were incubated at room temperature for 15 minutes in the dark.  
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All tubes were washed with MACS buffer and spun down, then repeated. All tubes had 
MACS buffer added, followed by straining through a 70m filter. 
 
Cells were sorted using the BD FACSAria into 0.2ml lo-bind DNA strip tubes, each tube 
containing 2.5l of RLT Plus Buffer for immediate cell lysis and protein denaturation. Cells 
were sorted into tubes containing this RLT Plus Buffer as this is lyses the cell and exposes 
the genomic DNA for future steps in the protocol. Each row of strips contained the following 
amounts of cells from left to right:  10000, 1000, 100, 10, 5, 1, 1, 1, as depicted in figure 2A.  
 
All following steps were performed in a UV-irradiated laminar-flow hood, with all equipment 
and reagents which could withstand UV-treatment were UV treated for a minimum of an hour 

















F) PCR Amplification E) Second Strand Synthesis
D) Exonuclease Treatment and 
Purification
A) HT29 Cell Sorting B) Bisulfite Conversion C) First Strand 
Synthesis/Preamplification






















DNA Bisulfite Conversion 
Bisulfite conversion was done directly onto lysed cells, as quantification of genomic DNA is 
not possible in single cell sequencing. The purpose of this step is to be able to distinguish 
Figure 2 | Overview of protocol followed for single cell bisulfite sequencing process. A) HT29 cells 
were sorted into varying amounts per tubes via BD FACSAria. B) Genomic DNA was bisulfite treated, followed by C) 
preamplification. D) Exonuclease and purification treatment is then performed to remove dimers and residual reagents. 
E) Second strand synthesis is followed by F) PCR amplification and subsequent sequencing and analysis of the library. 
Adapted from [3]. 
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methylated cytosines from unmethylated cytosines. Genomic DNA from the cells is treated 
with sodium bisulfite, resulting in the DNA becoming single-stranded and fragmented.  
Unmethylated cytosines are deaminated, converting them to uracil’s, which post-PCR 
amplification will appear as thymine’s. Methylated cytosine’s will not be affected by the 
sodium bisulfite treatment. Therefore, upon sequencing, the cytosines present will only be 
methylated cytosines. This process can be seen in figure 2B.  
 
The Zymo EZ-methylation kit was used. 790l of M-solubilization Buffer and 300l of M-
Dilution Buffer was added to the CT conversion powder vial. Vial was wrapped in tin foil 
and shaken for 10 minutes until all particles completely dissolved. 160l of M-Reaction 
Buffer was added to vial post-shaking.  
 
7.5l of water was added to each lysate sample, followed by 65l of the CT conversion 
reagent. Samples were incubated on a thermocycler as follows:  
98oC for 00:08:00 
 65oC for 03:00:00 
 4oC hold. 
50l of Zymo Magbinding beads was added to 3ml of M-Binding buffer. 305l of this 
mixture was added to each sample, then incubated for 5 minutes at room temperature. Beads 
were then palleted, followed by supernatant removal and an ethanol wash. 100l of M-
Desulphonation buffer was added to each sample, then incubated for 15 minutes. Following 
this, beads were pelleted and washed twice with ethanol. Beads were then dried at 60oc for 10 







Samples were incubated with first strand synthesis mix for 5 minutes; beads were pelleted 
and 20l supernatant was transferred to fresh lobind PCR tubes. 20l of first strand synthesis 
mix was added to beads again and the process was repeated once more – leaving a total of 
40l of supernatant in each sample.  
 
First strand oligonucleotide sequence: /5SpC3/CT ACA CGA CGC TCT TCC GAT CTN 
NNN NN (HPLC purification). 
 
First Strand Synthesis / Preamplification 
The purpose of this step is preamplification of the genomic DNA post-bisulfite treatment. 
This limits the loss of informative sequences which are usually lost when bisulfite conversion 
is completed after adaptor tagging, conserving the complexity of the libraries. A 
complementary strand is synthesised via random priming and extension to the fragmented 
BS-converted DNA. These strands are primed by oligonucleotides which contain Illumina 
adaptor sequences at the 5’ end and a 3’ stretch of six random nucleotides. There are five 
rounds of amplification, illustrated in figure 2C, to maximize the number of tagged strands 
and to create multiple copies of each fragment.  
 
Reagent Amount per sample Amount for 10 (9+1 for 
error) 
Nuclease Free Water 32.8l 328l 
10x Blue Buffer 4l 40l 
dNTP mix (10mM each) 1.6l 16l 
First strand Oligo (10uM) 1.6l 16l 
Total 40l 400l 
Table 3. Reagents used for first strand synthesis. 
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Samples were placed on thermocycler at 65oc for 3 minutes then immediately cooled on an 
ice block. 1l of Klenow exo- (50 U/l, Enzymatics) was added to each sample, then 
incubated on a thermocycler as follows:  
4oC 00:05:00  
 Slow ramp from 4oC to 37oC at 15s per 1oC 
37oC 00:30:00  
4oC hold. 
Following incubation, samples were heated to 95oc for 45 seconds then immediately cooled 




Samples were incubated on a thermocycler as follows:  
Reagent Amount per Sample Amount for 10 Amount for 5 
rounds 
Nuclease free water 0.65l 6.5l 32.5l 
10x Blue Buffer 0.25l 2.5l 12.5l 
dNTP mix (10mM 
each) 
0.1l 1l 5l 
First strand oligo 
(10uM) 
1l 10l 50l 
Klenow exo- 
(50U/ul) 
0.5l 5l 25l 
Total 2.5l 25l 125l 
Table 4. Reagents used for preamplification of DNA. 
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4oC 00:05:00  
Slow ramp from 4oC to 37oC at 15s per 1oC 
37oC 00:30:00  
 
The process of samples being once again heated to 95oc for 45 seconds and cooled, followed 
by the addition of 2.5l mastermix and the thermocycler incubation is repeated an additional 
three times, totalling four rounds. For the fifth and final round, the final round of PCR was 
incubated for an additional hour, as follows: 
4oC 00:05:00  
Slow ramp from 4oC to 37oC at 15s per 1oC 
37oC 01:30:00  
4oC hold. 
 
 Exonuclease Treatment  
The purpose of this step is for the Exonuclease I enzyme to degrade any remaining primers or 
oligonucleotides which did not get incorporated during the first strand synthesis step. This is 
important otherwise dimer adaptor molecules such as those displayed in figure 3D would be 
synthesised.  
 
50l of the following Exonuclease mix was added to each sample: 
 
Reagent Amount per sample Amount for 10 
Nuclease free water 48l 480l 
Exonuclease I (NEB)  2l 20l 
Table 5. Reagents used for exonuclease treatment. 
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Total 50l 500l 
 




First Strand Purification 
This step allows for the likes of buffers, nucleotides, degraded primers and enzymes to be 
washed away. This ensures only tagged strands are present for the second strand purification. 
 
AMPureXP beads were equilibrated to room temperature for 10 minutes. 70l of AMPureXP 
beads were added to samples, then incubated at room temperature for 10 minutes. Beads were 
palleted and washed twice with ethanol. Supernatant was removed and beads were air dried at 
50oC for 5 minutes.  
 
Second Strand Synthesis 
The second strand oligo is the second adaptor which is integrated similarly to the first strand 
adaptor for the same purpose, shown in figure 2E. 
 
49l of the following second strand master mix was added to each sample: 
 
Reagent Amount per sample Amount for 10 samples 
Nuclease Free Water 40l 400l 
10x Blue Buffer 5l 50l 
Table 6. Reagents used for second strand master mix. 
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dNTP mix (10mM each) 2l 20l 
Second Strand Oligo 
(10uM) 
2l 20l 
Total 49l 490l 
  
Samples were incubated for 10 minutes at room temperature to elute DNA from beads. 
 
Second strand oligo sequence: TGC TGA ACC GCT CTT CCG ATC TNN NNN N (HPLC 
Purification). 
 
Samples were then incubated on a thermocycler at 98oC for two minutes, followed by 
immediate cooling on an ice block. 0.5l of Klenow exo- (50U/l, Enzymatics) was added 
then incubated as following: 
4oC 00:05:00  
 Slow ramp from 4oC to 37oC at 15s per 1oC 
 37oC 01:30:00  
 4oC hold.  
 
Second Strand Purification 
700l of AMPure Buffer (AMPure XP beads supernatant) was added to 500l of nuclease 
free water. 120l of this mixture was added to each sample, mixed thoroughly and incubated 
at room temperature for 10 minutes. Beads were then palleted, washed twice with ethanol and 





In this final step, the pre-amplified bisulfite treated DNA is amplified to create a sufficient 
amount of DNA for sequencing. Different index primers are incorporated into each individual 
sample, allowing samples to be combined during sequencing yet still distinguishable from 
one another at later analyses. This step is depicted in figure 2F.  
 
Beads were then resuspended in 48l of the following PCR mastermix:  
 
 
Reagent Amount per sample Amount for 10 samples 
Nuclease free water 22l 220l 
KAPA Hifi Ready Mix 25l 250l 
PE1.0 (10uM) 1l 10l 
Total 48l 480l 
Table 7. Reagents used for PCR mastermix. 
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PE1.0 Sequence: AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA 
CAC GAC GCT CTT CCG ATC*T (HPLC Purification). Primer contains the full Illumina 
P5 and PE read 1 sequence.  
 
2l of iTag indexing primer (5M) was added to each sample. The following indexes were 
added corresponding to the sample they were put in i.e., iTag index primer 1 was added to 
sample 1 and iTag index primer 2 to sample 2.  
 
 













































Table 8. iTag indexing primers used for each sample. 
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Samples were incubated with indexing primers for 10 minutes at room temperature to elute 
DNA from beads. 
 
Samples were then incubated on the thermocycler as follows: 
 95oC 00:02:00 
16 Cycles of: 
 94oC 00:01:20 
 65oC 00:00:30  
 72oC 00:00:30  
Followed by: 
 72oC 00:03:00  
 4oC hold.  
33.6l of AMPureXP beads were added to each sample, then incubated at room temperature 
for 10 minutes. Beads were palleted, then washed twice with ethanol. 20l of nuclease free 
water was added to each sample for 10 minutes to elute DNA from beads. Beads were 
palleted and DNA containing nuclease free water supernatant was removed and transferred 
into a fresh PCR tube. Purifying process was repeated once more, so a total of 40l of the 
final library was in each tube.  
 
2.4 2100 Agilent High Sensitivity DNA Bioanalyser 
Samples were analysed using a qubit fluorometer to quantify the amount of DNA present in 
each sample. The NanoPhotometer was then used to assess the purity of each sample. 
Following this, the Agilent High Sensitivity DNA Kit was used to check the library size 




Samples with Qubit concentrations greater than 0.3 ng/l, with appropriately sized fragments 
(300 – 500 bp) were selected for library preparation for MiSeq. The final library pool was 
diluted to 40l (1.5nM) in preparation for iSeq sequencing. 
 
2.5 Illumina iSeq Sequencing 
The multiplexed library was sequenced via Illumina iSeq Sequencer, performed by Rob 
Weeks (Department of Pathology, University of Otago).  
 
2.6 Publicly Available Data Analyses 
Publicly available single cell methylation data was obtained from Bian, Hou [1]. The scTrio-
Seq data was obtained from the NCBI Gene Expression Omnibus (GEO) using accession 
number GSE97693. A table of the selected cells from each subregion is displayed in table 9.  
 
The average methylation status of genes and their promoters was determined by finding the 
average level of methylated versus unmethylated CpG sites within the promoter/gene region 
in question based on ENSEMBL gene and promoter regions. A methylation of 0 meant no 
CpG sites were methylated within the region. A methylation of 1 meant all CpG sites within 

















507 NC GSM2697695  SRR5825131   
509 NC GSM2697696  SRR5825132   
517 NC GSM2697697  SRR5825133   
521 NC GSM2697698  SRR5825134  
525 NC GSM2697699  SRR5825135   
527 NC GSM2697700  SRR5825136   
529 NC GSM2697701  SRR5825137   
213 PT1 GSM2697711  SRR5825147  GSM2697231 
229 PT1 GSM2697719  SRR5825155  GSM2697237  
230 PT1 GSM2697720  SRR5825156  GSM2697238  
324 PT2 GSM2697745  SRR5825181   
484 PT2 GSM2697752  SRR5825188  GSM2697285 
559 PT2 GSM2697767  SRR5825203   
336 PT3 GSM2697772  SRR5825208   
347 PT3 GSM2697780  SRR5825216  GSM2697308  
376 PT4 GSM2697809  SRR5825245   
420 PT4 GSM2697826  SRR5825262   
166 LN1 GSM2697488  SRR5824924  GSM2696959  
167 LN1 GSM2697489  SRR5824925  GSM2696960  
175 LN1 GSM2697493  SRR5824929   
176 LN1 GSM2697494  SRR5824930   
183 LN2 GSM2697496  SRR5824932   
457 LN2 GSM2697509  SRR5824945   
268 LN3 GSM2697511  SRR5824947   
441 LN3 GSM2697513  SRR5824949   
270 LN3 GSM2697512  SRR5824948   
442 LN3 GSM2697514  SRR5824950   
33 ML1 GSM2697528  SRR5824964  GSM2697017  
36 ML1 GSM2697531  SRR5824967  GSM2697020 
73 ML2 GSM2697541  SRR5824977  GSM2697051  
76 ML2 GSM2697542  SRR5824978  GSM2697053  
116 ML3 GSM2697549  SRR5824985  GSM2697078 
117 ML3 GSM2697550  SRR5824986  GSM2697079  
148 ML4 GSM2697571  SRR5825007  GSM2697104  
141 ML4 GSM2697565  SRR5825001   
149 ML4 GSM2697572  SRR5825008  GSM2697105 
150 ML4 GSM2697573  SRR5825009  GSM2697106  
223 MP1 GSM2697615  SRR5825051  GSM2697152  
Table 9. CRC patient cells chosen for analysis from public dataset. Data 











2.7 Statistical Analysis 
One-way ANOVA followed by a Tukey’s multiple comparison test was used to compare the 
methylation differences between normal adjacent tissue, primary tumour and distant 
metastases. P-values of <0.05, <0.01, <0.001 and <0.0001 were considered statistically 
significant. 
 
Pearson’s correlation co-efficient tests were performed between methylation and expression 










217 MP1 GSM2697611  SRR5825047  GSM2697148  
36 MP2 GSM2697650  SRR5825086   
52 MP2 GSM2697658  SRR5825094   
103 MP3 GSM2697661  SRR5825097   
105 MP3 GSM2697663  SRR5825099  GSM2697199  
80 MP4 GSM2697669  SRR5825105  GSM2697204  
204 MP4 GSM2697683  SRR5825119  GSM2697214 
112 MP5 GSM2697689  SRR5825125  GSM2697220  
116 MP5 GSM2697692  SRR5825128  GSM2697223  
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Chapter 3: Results 
3.1 Implementation and Optimisation of Single Cell Bisulfite Sequencing Protocol 
The following chapter addresses aim one of my thesis; to implement and optimise the 
single cell bisulfite sequencing protocol. The succeeding subsections describe the 
steps taken to prepare for implementation of the protocol, as well as the process of 
optimisation. 
 
3.1.1 Fluorescence Activated Cell Sorting 
This section explores the sorting of the human colorectal cancer cell line described in aim 1 
of my thesis. A range of cell amounts were sorted based on a live-dead stain to ensure viable 







Figure 3 shows live-dead staining for FACS of HT29 cells. A live-dead FVS450 stain was 
used to discriminate between live and dead cells. FVS450 discriminates between live and 
dead cells as non-viable/dead cells will have a higher uptake of the dye due to permeable cell 
membranes, whereas live cells will have less permeable membranes. Figure 3A shows 
positive control cells, which did not receive any FVS450 dye. As live cells are less likely to 
take up the dye due to their intact membranes, the unstained cells give reference for what 
fluorescence live cells will take as they will appear unstained. Figure 3B contained heat killed 
cells, which were exposed to the FVS450 dye. The heat-killed cells, like other non-viable 
Figure 3 | FACS Sorting of HT29 cells using FVS450 dye to select for viable live cells. A) 
Positive control. Unstained for viable HT29 cells. Events = 6,132. B) Negative control. Heat 
killed HT29 cells with high fluorescence. Events = 5,411. C) Contains entire sample population 
of HT29 cells for sorting – both live and dead. D) Uptake of FVS450 allowed for live and dead 




cells, had permeable membranes resulting in a high uptake of FVS450 dye and consequently 
higher fluorescence. This acted as a reference point for at which fluorescence a cell was 
considered non-viable.  Figure 3C displays the entire population of HT29 cells exposed to 
FVS450 dye. Figure 3D depicts the segregated live and dead cell population based on their 
fluorescence. Cells which were deemed viable were then sorted into tubes containing either 1, 
5, 10, 100, 1000 or 10,000 cells.  
 
3.1.2 Optimisation of Single Cell Bisulfite Sequencing Protocol 
With respect to the optimisation component of my first aim, the following section explores 
the steps taken to improve and eventually successfully implement the single cell bisulfite 
sequencing protocol. It explores each attempts successes and failures, guiding future direction 
for refinements of the protocol in the following attempt.  This section focuses largely on the 
use of the 2100 Agilent Bioanalyzer High-Sensitivity DNA chip profiles to indicate if the 
protocol has been successful in creating high-quality libraries.  
 Figure 4  | Agilent 2100 Bioanalyzer profiles for single cell bisulfite libraries. Library 
profiles of HT29 single cells post-whole genome bisulfite amplification. Attempt 1. 




Results from the first attempt were clamorous, however this was expected for the first attempt 
at a complex protocol. Following these results, extra precautions were taken to irradicate 
contamination as much as is feasible. This included increasing periods of UV irradiation of 
all reagents and equipment capable of withstanding UV-irradiation to two hours. Those not 
able to withstand UV were cleaned with ethanol frequently. This was done to reduce the large 
amount of contamination resulting in the sharp messy peaks in the bioanalyser profiles of 






While attempt two (figure 5) did not show signs of a successfully amplified single cell 
library, that being a smooth peak around 300 – 500 bp mark, in contrast to the earlier 
Bioanalyzer profile, contamination appeared to be significantly reduced. However, almost all 
the bioanalyzer profiles in this attempt had sharp peaks near to the lower marker. This is most 
likely residual adapters which were not correctly washed away. According to the protocol, 
Figure 5 | Agilent 2100 Bioanalyzer profiles for single cell bisulfite libraries. The 
library profiles of HT29 single cells post-whole genome bisulfite amplification. Graphics 
show library size distribution. Attempt 2. No peak library length as cells were not successfully 




the sharp peaks are often a result of having the incorrect ratio of AMPureXP beads during 
purification steps, resulting in left over fragments and oligo concatemers not being removed. 
Also, likely reflecting the less noisy profiles, the lower and upper markers have worked to a 
much higher standard than the previous attempt.  
 
For the next attempt (figure 6), the number of transfer steps in the protocol was reduced. The 
purpose of this was to minimise the opportunities for sample loss to occur as a result of 
transferring between tubes. Also, extra care was taken when pipetting the AMPureXP beads 









Figure 6 | Agilent 2100 Bioanalyzer profiles for single cell bisulfite libraries.  Library 
profiles of HT29 cells post-whole genome bisulfite amplification. Graphics show libraries 
size distribution. Attempt 3. Libraries each contain a single cell. ‘-‘ denotes an empty 




Sample 3 in figure 6 appears to have a smooth peak just after the lower marker. While the 
smooth and gradual curve is what you would expect to see, it is peaking at less than 200 bp. I 
would expect to see a curve that is greater than 200 base pairs with a mean length of 300-600 
base pairs and a smooth profile. Additionally, many of the samples, bar 3 and 4, had faulty 
lower and upper markers.  
 
Following this, cells were resorted via FACS once again. However, they now started with a 
high number of cells and gradually declined; as 10,000, 1000, 100, 10, 5, 1, 1, 1. This was 
done to see at what number of cells the protocol ceased to amplify the DNA. It also would 
provide a positive control as if the 10,000 did not work, there was likely an issue with the 







The results from Table 10 showed the concentration of the negative control was too low to 
detect, as expected. However, single cell 1A also had too little DNA to detect, suggesting the 
DNA was lost at some point or degraded during the bisulfite conversion. Single cell 1B and 
1C had expected concentrations - low but still detectable – however, the 5 cell, 10 cell, 100 
cell and 1000 cell samples unexpectedly had less DNA present than single cells 1B and 1C.  
 
Samples were once again run on the Agilent 2100 High-Sensitivity DNA Bioanalyzer to 
determine the fragment length and quality of the libraries, depicted in figure 7.  





Concentration too low 
for qubit to detect. 
2.0 1.6 
Single cell 1A  Concentration too low 




0.642 1.6 1.4 
Single cell 
1C 
0.294 1.8 1.6 
5 cells 0.116 2.18 1.4 
10 cells 0.252 1.8 1.4 
100 cells  0.286 1.7 1.8 
1000 cells Concentration too low 
for qubit to detect. 
1.78 1.6 
10,000 cells 5.52 1.98 1.6 
Table 10. NanoPhotometer Purity Readings and Qubit Concentrations for each 









As a result of the smooth curve of sample 3 from the previous attempt (figure 6), despite its 
lower molecular fragment size, it was rerun. As shown in figure 7, upon rerunning it the 
library presented with a much sharper peak around the 400 – 500 base pair mark, rather than 
the smooth gradual peak observed in the last run. This was true for both the diluted sample 3 
and non-diluted sample 3. The originally seen smooth curve may have been a result of 
impaired lower and upper markers in the Bioanalyzer run from attempt 3. Despite this, single 
cell 1B showed a promising potential result, with its library average fragment size ranging 
from 300 – 600 bp, with a smooth gradual peak. Although it is not a high peak, it is 
synonymous to the embryonic stem cell examples of a high-quality library on the 2100 
Bioanalyzer provided in the protocol. Some small peaks were observed around the 150 bp 
Figure 7 | Agilent 2100 Bioanalyzer profiles for single cell bisulfite libraries. The library 
profiles of HT29 cells post-whole genome bisulfite amplification. Graphics display libraries 
size distribution. Attempt 4. Samples 1A, 1B, 1C, “sample 3” and “sample 3 diluted” all contained 
single cells. Other graphs have number of cells present denoted above them. Lower marker 
= sharp peak at 35 bp, upper marker = sharp peak at 10380 bp. Negative control = nuclease 




mark as in previous attempts, indicative of adapters, yet these were very short peaks in 
comparison.  
 
The 10,000-cell library of figure 7 had a relatively smooth curve between the 300 bp and 700 
bp region, indicative of a high-quality library. While single cell 1B also held potential, it was 
unexpected that the protocol would drop off after the 10,000-cell sample, considering some 
bulk sequencing methods can capture 1000 cells. I had expected it to drop off potentially 
around the 10 – 100 cell amounts.  
 
Following the figure 7 bioanalyser results which showed the protocol dropped out at a much 
higher cell count than anticipated, the amount of transfer steps was once again reduced in an 
effort to minimise the opportunities for loss of DNA. As well as this, troubleshooting for the 
protocol suggested increasing PCR cycles if cells have been brought up from frozen, as my 

















Table 11 showed libraries with DNA concentrations more consistent with their original cell 
count when compared to the previous attempt, in table 10. As well as this, the purity readings 
were more consistent. The A260/A280 suggested the libraries were relatively pure, while the 
A260/A230 readings were slightly low in some samples. This could be a result of using an 
incorrect blank sample which did not match the pH and ionic strength of the samples.  
 
These libraries were then run on the Agilent 2100 Bioanalyzer, as well as single cell 1B from 
attempt 4’s libraries which showed potential. Single cell sample 3 from attempt 3 was also 
once again ran to confirm if it was a potential high-quality library or not. 
 
 





Concentration too low for 
qubit to detect. 
1.8 1.6 
Single cell 1A  1.59 1.8 1.8 
Single cell 1B 1.07 1.9 1.6 
Single cell 1C 0.52 1.8 1.4 
5 cells 3.34 1.8 1.4 
10 cells 1.08 1.9 1.4 
100 cells  0.676 1.9 1.4 
1000 cells 4.28 1.8 1.6 
10,000 cells 9.08     1.8 2.0 
Table 11. NanoPhotometer Purity Readings and Qubit Concentrations for each sample 










Following the previously stated adjustments to the protocol, figure 8 showed the 1000 cells, 
100 cells, 10 cells, 5 cells, single cell 1A, 1B and single cell 1B (old) had promising 
bioanalyzer results. That being, smooth profiles between the 300-600 bp mark. Most profiles 
had sharp peaks at the 150 bp mark, indicative of residual adapters. These can be trimmed 
later in the pre-processing step after sequencing. The negative control only showed peaks at 
the lower and upper base pair markers. As such, it is unlikely any peaks in other samples 
would be a result of contamination. This excludes sample 3 and (old) 1B as they were 
prepared in earlier rounds of the protocol. 
 
Figure 8 | Agilent 2100 Bioanalyzer profiles for single cell bisulfite libraries.  The library 
profiles of HT29 cells post-whole genome bisulfite amplification. Graphics show libraries 
size distribution. Attempt 5. Lower marker = sharp peak at 35 bp, upper marker = sharp 
peak at 10380 bp. Peak library length typically 300 – 600 bp. Negative control = nuclease 




Following these results, the eligible samples: 1B (old), 1B, 1A, 5 cells, 10 cells, 100 cells and 
1000 cells, went on to be sequenced using iSeq.  
 
This chapter has described the methods used to achieve the first aim of my thesis; to optimise 
and implement the single cell bisulfite sequencing protocol on a human sorted CRC cell line. 
To summarise, a combination of adjustments were introduced to the protocol after each 
attempt, which allowed for the acquisition of high-quality libraries. 
 
3.1.3 Low coverage next generation sequencing (using Illumina iSeq) of Single Cell 
Bisulfite Sequencing Cell Libraries. 
Due to time constraints as a result of COVID, I was unable to get the sequences from my 
libraries back in time to pre-process them.  
 
3.2 Bioinformatic Analysis of CRC Single Cell Patient Data 
Upon completion of the first aim, the second aim to bioinformatically analyse the single cell 
data to uncover heterogeneity that would otherwise be missed in bulk population sequencing 
could not be completed. This was due to COVID-19 delays preventing the sequencing and 
pre-processing of my samples in time. Therefore, instead of bioinformatically analysing my 
own data, I analysed a publicly available data set from a group which used single cell multi-
omic methods on CRC patients [1]. This group used the method of scTrio seq – a method 
which captures the genome, DNA methylome and transcriptome of a single cell. Data from 
12 CRC patients was obtained. This data was used to demonstrate what would have been 




All CRC patients were stage III or stage IV. Where possible, they obtained single cells from 
each of the patients’ adjacent normal colon tissue (NC), primary tumour (PT), lymph node 
metastases (LN), liver metastases (ML) and liver metastases post chemotherapy treatment 
(MP). Different areas of the sampling regions were sequenced, depicted numerically; for 
example, PT1 and PT2 are different areas of the primary tumour. Single cells from all regions 
were only obtained for patient CRC01, therefore I decided to use this data set in my 
bioinformatic analyses. In the interest of limited time due to COVID lockdown, analysing all 
cells from the patient let alone the entire dataset was unattainable. Considering this, I selected 
the top 10 cells from each sampling region based on the cells with the top mapping 
efficiency/genome coverage to demonstrate DNAme heterogeneity between CRC cells. The 
cells chosen for this were provided in table 9. I also chose a relatively even spread of 
different areas of the sampling region, to evenly represent the sampling region and investigate 
intra-tumour heterogeneity. The dataset was filtered to only contain methylation status in 
CpG contexts, as these are typically in promoter regions and influencing gene expression. 
This data set also provided the corresponding transcriptome for cells that they were able to 
obtain both the methylome and transcriptome for. 
 
3.2.1 Investigating Global Methylation of CRC Single Cell Patient Data 
As stated earlier, the regulation of the cancer genome as a whole is grossly dysregulated. In 
the following section, I explore patterns between single cell DNAme on a global and 







Both the primary tumours cells as well as the distant metastases displayed significantly less 
methylation globally compared to the matched normal adjacent colon tissue in figure 9 (p-
value <0.01). Interestingly, we see the primary tumour (PT) cells tend to have more variation 
of global methylation between them compared to distant metastases cells. One cell had as 
little as 0.4 global methylation while its highest was around 0.6, surpassing the normal 
adjacent colon (NC) samples median global methylation. The distant metastases: lymph node 
(LN), liver metastases (ML) and liver metastases post-treatment (MP), showed very little 
variance and had very similar median global methylation rates, around 0.5. 
Figure 9 | Average global methylation of each single cell from each sampling region. NC = 
normal adjacent colon tissue, PT = primary tumour, LN = lymph node metastases, ML = liver 
metastases, MP = liver metastases post-treatment. Methylation scaled 0-1, 0 being no 
methylation and 1 being full methylation across CpG sites. Statistical significance was obtained 
using a one-way ANOVA followed by a Tukey’s multiple comparison test. **  = p-value < 0.01. 





NC single cells clearly stand out in figure 10 compared to the carcinogenic regions as having 
higher methylation of their chromosomes. Curiously, some cells from different regions of the 
ML had methylation levels almost matching that of NC tissue (figure 10). Also, the majority 
of single cells from the PT tissue appear to have relatively more hypomethylated 
chromosomes compared to distant metastases tissues (LN, ML and MP). Inverse to this, 
another single cell from the PT tissue had high methylation levels across chromosomes, 
matching that of NC tissue (figure 10).  
 
Figure 10 | Heatmap of average chromosomal methylation for each cell from each region. 
X-axis contains each cell. NC = normal adjacent colon tissue, PT = primary tumour, LN = lymph 
node metastases, ML = liver metastases, MP = liver metastases post-treatment. Number 
following region depicts different areas of that region being sampled. Number following 
underscore is number of that single cell. Colour depicts average methylation of single cell at 




 In terms of chromosomal trends of hypomethylation, there appears to be no obvious single 
chromosome which is more susceptible to hypomethylation in this group of single cells 
(figure 1-).  
 
These results were clearly consistent with current literature that observes a global 
hypomethylation shift in neoplastic cells from normal adjacent colon tissue, even from early 
stages. This section additionally highlighted that while this phenomenon is observed, there is 
different global methylation patterns between cells both intra- and inter- tumourally.  
 
3.2.2 Investigating Differentially Methylated Genes in CRC Patient Single Cells.  
Having explored the single cell variation of methylation states on a larger scale, let us now 
consider the methylation states of commonly aberrantly methylated genes in CRC between 
single cells. As alluded to earlier in this thesis, focal hypermethylation of genes is a common 
occurrence in neoplastic cells, as is loss of methylation on imprinted genes. This section 














The E-cadherin gene, CDH1, as described earlier as typically being a point of focal 
hypermethylation was explored (Figure 11A). The CDH1 promoter region was defined on 
ENSEMBL (ENSG00000039068) using Hg19. There was no significant difference in 
promoter hypermethylation between normal tissue, the primary tumour, or its distant 
metastases. Normal tissue and primary tumour samples appeared to have the greatest 
variation of CDH1 promoter methylation per cell. The median CDH1 promoter methylation 
of the single cells from ML was the highest of all the regions (0.0.7), while the median of 
single cells from the primary tumour was the lowest, at 0.55. Although, these were not 
statistically significant. The PT region had one cell with very low methylation of 0.3 at the 
CDH1 promoter, yet another PT single cell had the highest methylation of all the cells, at 0.8.  
Figure 11 | CDH1 Promoter Methylation and Expression Data from Single Cells of each 
Sampling Region. A) Average CDH1 promoter methylation of each cell from each sampling region. 
B) Expression of CDH1 transcript vs. promoter methylation of cells with available expression data. 
NC = normal adjacent colon tissue, PT = primary tumour, LN = lymph node metastases, ML = liver 
metastases, MP = liver metastases post-treatment. FPKM = Fragments per kilobase of exon per million 
mapped fragments. Methylation ranges from 0-1, 0 being no methylation and 1 being full methylation 
of CpG sites across CDH1 promoter. Statistical significance was obtained using a one-way ANOVA 
followed by a Tukey’s multiple comparison test, found no statistically significant differences between 






The cells which had corresponding expression data available were analysed for expression of 
the CDH1 transcript, which included cells from the PT, LN, ML and MP. The only single 
cells with CDH1 expression were from sample regions PT and ML. All CDH1 promoter 
methylation levels fall between 0.5 to 0.8, with no positive or negative correlation to the 
amount of CDH1 transcript being expressed (Pearson’s correlation co-efficient = 0.07). In 
fact, the highest expression of the CDH1 transcript was in ML samples, which had the 
highest median CDH1 promoter methylation in figure 11B.  
 
Some ML cells had 100-fold less CDH1 transcript present compared to other ML cells 
(Figure 11B). Similarly, some PT cells had 0 transcript present, while another had 70 FPKM.  
Figure 12 | MLH1 Promoter Methylation and Expression Data from Single Cells of each 
Sampling Region.  A) Average MLH1 promoter methylation of each cell from each sampling 
region. B) Expression of MLH1 transcript vs. promoter methylation of cells with available 
expression data. NC = normal adjacent colon tissue, PT = primary tumour, LN = lymph node 
metastases, ML = liver metastases, MP = liver metastases post-treatment. FPKM = Fragments per 
kilobase of exon per million mapped fragments. Methylation scaled 0-1, 0 being no methylation and 
1 being full methylation of CpG sites across the MLH1 promoter. Statistical significance was 
obtained using a one-way ANOVA followed by a Tukey’s multiple comparison test, showing no 





All LN and MP cells with expression data available had little to no expression of CDH1 
transcript, irrespective of the CDH1 promoter methylation status.  
 
The MLH1 promoter region was defined using ENSEMBL (ENSG00000076242) aligned to 
Hg19. The MLH1 promoter returned no statistically significant differences in the level of 
methylation (figure 12A). Although not statistically significant, the PT and distant metastases 
tended to have higher median promoter methylation compared to NC cells. NC and MP cells 
had a similar median MLH1 promoter methylation of 0.6, while PT, LN and ML had similar 
median MLH1 methylation of 0.7. Two single cells in the PT region had the highest MLH1 
promoter methylation, at 0.8. However, some cells in the PT region also had low methylation 
of this promoter at 0.5, synonymous with NC tissue cells.  
 
One cell from the ML tissue had 50 FPKM of MLH1 transcript present, despite having a 
relatively high level of promoter methylation, at 0.75 (figure 12B). Another ML cell had 
relatively high MLH1 transcript present of 100 FPKM, with a methylation level similar to 
that seen in NC cells of 0.55. Majority of cells with MLH1 expression data available had little 
to no expression of MLH1 transcript, irrespective of the MLH1 promoter methylation. This 











The CD276 promoter region was defined using ENSEMBL (ENSG00000103855) aligned to 
Hg19. The primary tumour and distant metastases single cells were significantly 
hypomethylated in comparison to the normal adjacent colon tissue with a decrease in CD276 
promoter median methylation of 40% (figure 13A) (p-value <0.01, p-value<0.001). The 
median CD276 promoter methylation of single cells from tumour samples ranged from 0.3 to 
0.4. Meanwhile, the median CD276 promoter methylation of NC cells was up at 0.85. There 
were still observed outliers, particularly in the LN and MP groups. Two LN single cells had 
CD276 promoter methylation around 0.85, while cells from this same group had methylation 
levels as low as 0.2. The MP group also had a single cell with methylation as high as 0.75, as 
well as cells with a methylation of 0.2.  
 
Figure 13 | CD276 promoter methylation and expression data per single cell in each region. A) Average 
CD276 promoter methylation of each cell from each sampling region. B) Expression of CD276 transcript 
vs. promoter methylation of cells with available expression data. NC = normal adjacent colon tissue, PT = 
primary tumour, LN = lymph node metastases, ML = liver metastases, MP = liver metastases post-treatment. 
FPKM = Fragments per kilobase of exon per million mapped fragments. Methylation scaled 0-1, 0 being no 
methylation and 1 being full methylation of CpG sites across CD276 promoter. Statistical significance was 
obtained using a one-way ANOVA followed by a Tukey’s multiple comparison test, ** = p-value <0.01, 




A slight correlation between CD276 methylation and CD276 transcript expression was 
observed with a Pearson’s correlation co-efficient of 0.33.One primary tumour cell had 
CD276 promoter methylation of 0.15, with a corresponding CD276 transcript expression of 
25 FPKM. Four cells from the ML tissue had CD276 promoter methylation of 0.2, 0.3, 0.45 
and 0.7 and corresponding CD276 transcript expression of 24, 7, 14 5 FPKM, respectively 






Figure 14 | IGF2 methylation status per cell in each region. NC = normal adjacent colon tissue, 
PT = primary tumour, LN = lymph node metastases, ML = liver metastases, MP = liver metastases 
post-treatment. Methylation scaled 0-1, 0 being no methylation and 1 being full methylation of CpG 
sites across IGF2. Statistical significance was obtained using a one-way ANOVA followed by a 




The methylation of the imprinted gene IGF2 was analysed in these cells (figure 14). This 
gene was defined using ENSEMBL (ENSG00000167244) aligned against Hg19. IGF2 
expression data was not included in figure 14 as all single cells with expression data available 
displayed little to no IGF2 expression, despite the difference in methylation between normal 
adjacent tissue and primary tumour tissue. Single cells from the PT region showed a 
significant decrease in median methylation of IGF2 compared to the NC single cell median 
methylation, with the single cells of PT methylation median at 0.5 and NC single cells 
median at 0.8. The NC tissue had relatively little variation of median IGF2 methylation 
between cells, ranging from 0.7 to 0.85. Whereas the PT had single cells median methylation 
ranging from as low as 0.22 to as high as 0.8, just below the NC median methylation of IGF2. 
Interestingly, there was so statistically significant difference between NC cells and the distant 
metastases. Single cells from the PT sample region had the lowest median of IGF2 
methylation amongst all the tissues at 0.5. One PT cell had substantially low IGF2 
methylation (methylation value = 0.25), which was the lowest methylation of IGF2 amongst 
the single cells.  
 
This chapter highlighted the vast amount of heterogeneity in both global and focal 
methylation contexts between single cells. Three key cancer phenomena were explored in the 
context of single cells. While the overall results are generally consistent with that seen in bulk 









Chapter 4: Discussion 
 
In the chapter that follows, I will present the principal findings from the implementation of 
the scBS-seq protocol, as well as the findings from the public scTrio-seq dataset and their 
relation to current literature. As well as this, limitations encountered throughout the project 
are discussed, followed by future directions.  
 
4.1 Generating high-quality single cell libraries  
Several aspects of a scBS-seq protocol were fine-tuned to improve the quality of the single 
cell libraries. This included: reducing contamination of the libraries, improving handling and 
enhancement of selection and amplification. The following section details the steps taken to 
optimise the scBS-seq protocol. 
 
The scBS-seq protocol is designed to amplify as little as 6pg of DNA, therefore even a small 
amount of contamination will easily become amplified. This makes the potential for 
contamination far higher than usual when using bisulfite sequencing protocols. I encountered 
this contamination amplification in my first attempt. The sharp random peaks and lack of 
lower and upper marker peaks in figure 4 suggested contamination of my samples. To 
address this problem, in the following attempt I increased the UV-irradiation time of 
equipment prior to the experiment from one to two hours, frequently changed gloves and 
cleaned anything that entered the cell-culture hood. Following attempts also had a negative 
control added to ensure there was no contamination. As a result of these adjustments, figure 
5, 7 and 8 showed improvements in the level of contamination, with much less noisy spikey 
bioanalyser profiles and much clearer lower and upper marker peaks. While there were still 
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occasional peaks in figures 5, 7 and 8 following these changes, they were around the 150 bp 
mark and short which is indicative of residual adaptors rather than contamination. 
 
Following the reduction of contamination, the next aim was to optimise the handling of the 
initial single cell DNA considering it involves treating 6 pg of DNA with harsh sodium 
bisulfite followed by amplification. This means, there are 5 steps before preamplification 
where the 6 pg of DNA could be lost. Figures 5 and 7 presented with libraries that only had 
lower and upper marker peaks, therefore I had lost the DNA at some point throughout the 
protocol. To address this, I removed transfer steps where possible. There were extra transfer 
steps in the protocol typically during bead purification. Therefore, I omitted two of the 
transfer steps between different tubes to minimise the chance of DNA loss due to remaining 
in the previous tubes. While figure 7 returned one single cell library (1B) which had a smooth 
curve between the lower and upper markers between 300 - 700 bp, no other samples 
displayed high-quality libraries (only had lower and upper marker peaks) apart from the 
10,000-cell sample. This was surprising, as I had expected to see at least samples with 100 
cells and upwards produce libraries. Although, this was an improvement to all previous 
attempts as I now had two libraries with smooth curves between 300 – 700 bp. As a result of 
this, I explored other areas of the protocol which may increase the yield from samples.  
 
As a result of the protocol not successfully amplifying below 1,000 cells in figure 7, I 
investigated troubleshooting advice for the protocol from the author. The author suggested 
increasing the number of final PCR cycles if tissue had been kept frozen for a considerable 
amount of time. The author also suggested to increase the cycles if using human tissue, as the 
protocol was implemented on a mouse genome which is smaller than the human genome. 
Therefore, I increased the number of final PCR cycles from 15 to 17. The author also 
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suggested ensuring the AMPureXP ratio was a 0.8x ratio, when I had been using a 0.7x ratio. 
Therefore, I also increased from 0.7x to 0.8x ratio in the next attempt. This would allow for 
better size selection of fragments between 300 – 700 bp. Following the adjustment 
AMPureXP ratio, increasing the number of final PCR amplifications, reducing transfer steps 
and gaining familiarity with the protocol, I was able to successfully amplify the samples 
containing single cells (1B old, 1B and 1A) 5 cells, 10 cells, 100 cells, 1000 cells and 10,000 
cells. This was shown in figure 8 as the above samples had smooth curves between the lower 
and upper base pair markers which were between 300 – 700 bp. To confirm the amplification 
observed was in fact my HT29 cell line, the libraries were sequenced using iSeq. A PhiX 
spike in was included due to samples being of low-diversity as a result of the BS-treated 
DNA. Unfortunately, the sequences were not retrieved back in time for pre-processing and 
adding to this thesis. 
 
In conclusion, taking steps to minimise opportunities for DNA loss, appropriate size 
selection, and increasing PCR amplification steps lead to the implementation of a scBS-seq 
protocol [81] on the human-sorted CRC cell line, HT29. 
 
4.1.1 Limitations and future directions for generating high-quality single cell libraries 
One major limitation that is currently unavoidable with bisulfite sequencing, is the amount of 
DNA and therefore information lost in the bisulfite conversion step. This limitation is 
amplified in single cell bisulfite sequencing, as there are only the two strands of DNA so 
once that information is lost, it cannot be supplemented by other DNA. While there are other 
methods for obtaining methylation data which are less harsh on the DNA, such as scMSRE 
described earlier which uses restriction enzyme digestion, this limits the number of CpG sites 




In the future, to increase the final concentration of the libraries, I could increase the number 
of final PCR cycles again. This however may introduce PCR amplification bias; therefore, I 
would decrease the final elution amount to obtain libraries with higher concentrations. In 
future I would use 15l of nuclease free water to elute the DNA, which is still a sufficient 
amount for the analyses using qubit, nanodrop, Agilent HS DNA bioanalyser and 
MiSeq/HiSeq to be performed.  
 
In order to see at which number of cells the protocol would successfully create high quality 
libraries, I included varying amounts of cells and a negative control. The acquisition of high-
quality single cell libraries was achieved finally towards the end of the year, if I was able to 
attempt the protocol again I would have replaced the higher cell number sample with other 
controls such as lambda phage as an unmethylated control, allowing for assessment of 
bisulfite conversion rates. Using an unmethylated lambda phage control checks that the C/T 
conversion rate is greater than 97%. I would have also added in negative controls at different 
points throughout the protocol, such as after each amplification to ensure there was no new 
contamination introduced after adding reagents at different steps.  
 
Additionally, the bioanalyzer profiles of the 1000 cell and 10,000 cell samples produced 
abnormal bioanalyser profiles towards the upper markers. This is expected, as when 
performing this protocol on samples with more than 1000 cells, the protocol suggested 
omitting the extra cycles of first strand synthesis, so it was only performed once [3]. The 
protocol also suggested reducing the number of final PCR amplifications. In future, this could 
be done to get tidier overall HS DNA bioanalyser profiles of higher numbers of cells, 
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however the protocol was kept consistently between samples to see at what number of cells it 
dropped off when I was not receiving any libraries.  
 
Another limitation of my implementation of the scBS protocol was the small number of cells 
that it can be performed on currently. Despite the success of the protocol, implementing it on 
as few as 9 samples took three days, with the first two days involving 10+ hours of lab work. 
While this low sample number was appropriate for my aim, to optimise and implement the 
protocol, future implementation on patient samples would require this to be on a much larger 
scale to investigate any clinically relevant results. However, this protocol is sufficient for the 
analysis of cells such as circulating tumour cells (CTCs), where very few are obtained from 
the blood at any given time.  
 
As a result of COVID delays elsewhere in the world even before the lockdown, getting 
certain reagents which were critical for the protocol took extended periods of time, especially 
considering some were specialised sequences with alterations such as HPLC purifying. As 
well as this, everything including the PCR machine needed to be kept in the cell-culture hood 
throughout each day. The protocol took a total of 3 days to get bioanalyzer profiles stage, 
with the first two days taking 10+. In a lab which shares limited cell culture hoods, it was 
difficult to book the hood out three full days of the week too often.  
 
4.2 Trends in methylation of single cells in CRC 
The scTrio-seq dataset [1] from CRC patients was used to explore DNAme patterns of 
commonly aberrantly methylated genes involved in pathways that contribute to the initiation 
and progression of CRC. Global as well as focal methylation patterns were explored, 




There are numerous exploited pathways which contribute to the development of CRC, 
commonly promoting genomic instability, activation of oncogenes and silencing of tumour 
suppressor genes. This analysis aimed to explore a range of these pathways; globally, 
imprinted genes, highly conserved genes, genes suspected to be involved in metastatic 
pathways, as well as DNA mismatch repair genes. This chapter aimed to investigate a wide 
scope of pathways known to contribute to carcinogenesis in CRC. 
 
4.2.1 Global methylation trends in single cells in CRC  
The universally accepted phenomenon in carcinogenic cells of global hypomethylation was 
highlighted clearly in my results. The global DNA methylation was stable between primary 
tumour cells and the metastasised cells with 50% global methylation, suggesting the global 
methylation status did not greatly influence the metastasis of cells. This is not unexpected as 
many studies have found global hypomethylation to be an early event in carcinogenesis, as 
early as in precancerous lesions [82]. This is reflected in my results where the major 
difference was observed between normal adjacent colon cells and tumour cells, with NC cells 
typically having upwards of 70% global methylation compared to 50% methylation in 
neoplastic cells. The emergence of single cell sequencing in the presence of this early onset 
phenomenon is instrumental in a clinical context. Being able to screen normal colon tissue for 
hypomethylation at a single cell level would allow for the identification of outlying globally 
hypomethylated cells, which may be beginning neoplastic transformation. The global 
hypomethylation of this small number of cells at early stages would otherwise be masked in 




Past studies have shown epigenetic alterations in tumours post-treatment which allows for 
drug-resistance of certain cells in the population [83, 84]. Despite this, there was no 
difference in global methylation between liver metastases cells and liver metastases cells 
post-treatment, although literature typically reports more focal epigenetic influences in drug 
tolerance rather than global  [85-87].  
 
The primary tumour displayed the greatest amount of intra-tumour heterogeneity in respect to 
global and chromosomal methylation per cell, with the lowest cell exhibiting 40% global 
methylation yet another with almost 70% global methylation. Cells from the same sampling 
region of the primary tumour (i.e., PT1) had, expectedly, the most similar chromosomal 
methylation. This was expected as cells from within the same region will be closer in lineage 
and are therefore more likely to be homogeneous. Interestingly, the PT2 region had cells with 
chromosomal methylation around 40%, compared to the PT3 region cells, which had a higher 
chromosomal methylation around 60-70%. This was able to show the contrast between cells 
from the same primary tumour tissue, highlighting intra-tumour heterogeneity which would 
have otherwise been masked and presented as an average methylation rate.  
 
Interestingly, 5 single cells from the liver metastases displayed higher chromosomal 
methylation upwards of 60%, compared to 40-50% global methylation seen at the primary 
tumour, lymph node and even liver metastases post-treatment cells. This may be a result of 
the vastly different environments in which the different cancer cells are required to grow in. 
However, this finding contradicts current literature which found liver metastases tended to 
have a late increase of hypomethylation accompanied by an increase of proto-oncogenes 




Previous literature has often described chromosomes more susceptible to chromosomal 
hypomethylation as well as chromosomal hypermethylation in CRC. Chromosomes 18 and 5 
have been described to display greater hypermethylation due to carrying frequently 
hypermethylated genes[90]. Whereas chromosomes 22, 17 and 15 were described as typically 
hypomethylated due to carrying frequently hypomethylated genes [90]. My results were not 
consistent with this literature, as no chromosome displayed consistent hypomethylation or 
hypermethylation across tumour cells compared to normal adjacent colon cells.  
 
In future, looking at the structural genomic alterations of the cancer genome as a result of this 
global hypomethylation could further explore the impact of demethylation beyond the scope 
of expression. Often, this global hypomethylation is more representative of repeat elements 
such as LINES and pericentromeric regions becoming demethylated and contributing to the 
structurally aberrant cancer genome, than hypomethylation of specific genes. Therefore, it 
would be interesting to compare the structural abnormalities of the cancer genome in the PT 
cell with the 0.25 methylation, compared to the other PT single cells with higher average 
global methylation and see if the chromosomal abnormalities reflected the lower global 
methylation.  
 
The concept of global hypomethylation being a trait of cancerous cells was gained through 
the sequencing of bulk populations of tumour and normal tissue. My results were consistent 
with this literature but were able to add a layer of information which displayed the 






4.2.2 Focal hypermethylation of single cells in CRC  
This section follows the findings from exploring genes which are commonly focally 
hypermethylated at their promoters in CRC. The presence of focal hypermethylation at 
certain gene promoters has been shown to act as biomarkers, alter gene expression and 
influence therapeutic response. This section discusses two commonly hypermethylated genes 
in CRC from my analysis, CDH1 and MLH1. 
 
I expected to see an increase in CDH1 promoter methylation of single cells from neoplastic 
tissues compared to normal colon, considering hypermethylation of CDH1 and loss of E-
cadherin has been reported frequently in CRC studies [47, 91, 92], with reports of as many as 
93% of patients displaying CDH1 promoter methylation and decreased E-cadherin expression 
[48]. The methylation of the CDH1 promoter region in my results, however, were sporadic. 
There was no obvious hypermethylation of the famous tumour suppressor gene. The lack of 
significant differences between groups in the CDH1 promoter methylation could be a result 
of different definitions of the promoter region. Additionally, I had a small sample size of cells 
per group (10 per tumour group, 7 for normal colon tissue), meaning a larger scale analysis of 
cells may have displayed promoter hypermethylation overall. The difference between my 
data and literature may also reflect the very aim of single cell sequencing; not every cell is 
going to have CDH1 promoter methylation, but identifying cells which do through the use of 
single cell technologies could have predictive power of future metastasis [91].  
 
The expression of the CDH1 transcript (E-cadherin) was still prevalent in >70% of primary 
tumour and liver metastases cells, therefore despite my results inconsistencies with the 
literature, the normal methylation of the CDH1 promoter correlates with E-cadherin still 
being expressed. On the contrary, some cells with 50% CDH1 promoter methylation had no 
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expression of E-cadherin, but it has been shown that CDH1 is also controlled by other 
elements such as TWIST1 and SNAI1 [93]. Overall, there was no discernible correlation 
between CDH1 promoter methylation and CDH1 expression (Pearson’s correlation co-
efficient = 0.07), highlighting the importance of not inferring gene expression on account of 
promoter hypomethylation.  
 
In an effort to explore another pathway which contributes to CRC initiation and progression, 
MLH1, a critical component of the DNA mismatch repair (MMR) system was analysed [94]. 
Previous literature surrounding MLH1 promoter methylation in CRC has been relatively 
conflicting, with some studies observing as little as 0.0% MLH1 promoter methylation [95] 
to as high as 66.9% [96].  Akin to the CDH1 promoter methylation, there was no significant 
differences between normal colon tissue and tumour tissue. The MLH1 promoter methylation 
of single cells fluctuated irrespective of the tissue they were from. While the data did not 
show significant differences in MLH1 promoter methylation between the neoplastic regions 
and normal tissue, the purpose of single cell sequencing is predominantly to recognise small 
populations or single cells which are outliers from the group. Acknowledging this, there were 
multiple cells from both the primary tumour tissue and liver metastases tissue which 
presented with hypermethylated MLH1 promoter regions (methylation = 0.85), which may 
render these cells more susceptible to microsatellite instability (MSI) [97], which could 
potentially give rise to a sub-population with that phenotype.  
 
It should also be acknowledged that MLH1 promoter methylation is largely influenced by 
location of the tumour, gender, and age of the patient. Typically, older, female CRC patients 
with right sided primary tumour location have hypermethylated MLH1 promoters [98]. I 
would have expected to see greater MLH1 promoter hypermethylation, as the patient data I 
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analysed was from a 50-year-old female, however with a left-sided primary site. One possible 
reason I did not see this hypermethylation, could reflect the patients BRAF/KRAS mutation 
status. MLH1 promoter methylation has shown evidence of being common in CRC patients 
with BRAF mutations [99], but less common in those with KRAS mutations [100]. The 
BRAF/KRAS status of this patient was not explored and therefore, the lack of MLH1 
promoter methylation may have reflected this. This could be explored in the future however 
as the genome sequence was also recovered in the scTrio-seq method.  
 
Albeit there was no observed difference in the MLH1 promoter methylation between normal 
colon and neoplastic tissues, the expression data is consistent with previous studies; with 
>90% of neoplastic cells showing no expression of MLH1 transcript. This means while the 
MLH1 expression is absent, it may not be a consequence of MLH1 promoter 
hypermethylation. Rather, as commonly reported, a genetic mutation inactivating MLH1 in 
CRC cells [101], which would explain the lack of correlation between promoter methylation 
and expression in my analysis (Pearson’s correlation co-efficient = -0.09).  
 
While there were no statistically significant differences between normal adjacent colon tissue 
and carcinogenic tissue methylation of the above genes, intra-tumour heterogeneity was 
observed across all genes of interest between all tissue regions.  
 
4.2.3 Focal Hypomethylation of Single Cells in CRC 
This section explores the inverse of the previous section, discussing the results of single cell 




The event of loss of imprinting (LOI) of imprinted genes has been thoroughly explored in 
cancer, with IGF2 being commonly studied [102]. I chose to explore this gene as it is a 
selective marker of CRC progression and staging [52], hence using single cell sequencing to 
identify small sub-populations of cells which may harbour such selective markers has 
relevant clinical implications. My analysis showed a significant drop in IGF2 methylation 
from a 85% median of normal colon tissue cells to a median of 50% in primary tumour cells 
(p-value < 0.001), consistent with published literature [103, 104]. Importantly, one cell 
displayed very low IGF2 methylation at 0.25, which has been shown to be associated with 
metastasis and correlated with high mortality [105]. In a clinical context, identifying the cells 
such as those with low methylation in the PT, LN and ML tissues may have prognostic 
significance.  
 
Despite the fact there was no expression of IGF2 despite a 35% decrease in methylation from 
normal tissue cells to primary tumour cells, it has been shown that LOI of IGF2 acts to 
increase expression of other genes involved in cellular proliferation, such as MCM5, MCM3, 
CDC6, LIG1 and CCNE1 [106]. This may explain why some studies have found a correlation 
between IGF2 LOI and increased IGF2 expression [107], yet a paradoxical expression of 
IGF2 has also been observed, where LOI of IGF2 in the tumour was associated with a 
decrease in IGF2 transcript compared to normal tissues [108]. LOI of IGF2 has also been 
associated with global chromatin instability, which may suggest the significant (p-value < 
0.001) 35% median methylation decrease contributes to the cancer genome in this way, rather 
than increased IGF2 expression [109]. IGF2 is also regulated by a DMR upstream of another 
imprinted gene, H19, which acts to repress it [110]. Therefore, IGF2 may have lost 
imprinting but the regulatory DMR upstream of H19 may not be hypermethylated, therefore 
still repressing IGF2 expression. In future, the methylation status of the DMR upstream of 
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H19 could be investigated [111]. Not only this, but previous studies have found IGF2 
transcription is controlled by several promoters [112]. Essentially, there are a number of 
reasons that may explain why no increase in IGF2 expression was observed in my data 
despite the significant decrease in methylation (p-value < 0.001). Using single cell 
sequencing to investigate the LOI trend in cancer is beneficial as contamination of tumour 
tissues with normal cells is likely to result in an underestimation of LOI. 
 
The cells from normal colon tissue had relatively homogeneous IGF2 methylation, with all 
cells bar one having median IGF2 methylation between 0.8 and 0.9. However, the primary 
tumour and its distant metastases cells showed greater heterogeneity between the single cells, 
having a 55% difference in median IGF2 methylation between their lowest methylated cells 
and highest methylation. This calls attention back to the highly heterogeneous nature of CRC, 
proving this heterogeneity is not observed in normal colon tissue and therefore it is not 
reflective of the tumours tissue of origin.  
 
Another commonly exploited normal biological pathway in CRC are immune checkpoints. 
The significant decrease in the methylation of CD276 promoter region between normal colon 
tissue and neoplastic tissues, is synonymous with recently published studies [113, 114]. 
CD276 is of interest as it has immunosuppressant functions [115] as well as aiding in 
metabolic reprogramming of cancer cells [116]. While there was a statistically significant 
drop in CD276 methylation of neoplastic tissues compared to normal colon (p-value < 0.01), 
most cells did not have high expression of CD276. There was evidence of a slight correlation 
between methylation of CD276 and CD276 transcript expression, with a Pearson’s 
correlation coefficient of 0.33.  Moreover, considering CD276’s immunosuppressant 
functions, I would have expected to see a higher expression of CD276 in the lymph nodes 
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considering these cells were under more stress from the immune system. Of note however, 
one cell had very low methylation level of 0.18 with a corresponding high CD276 mRNA 
expression, of 25 FPKM. Cells with these properties have been shown to be associated with 
poor prognosis [113], and this would have otherwise been masked had it been sequenced with 
the bulk population. This is also clinically relevant as CAR-T therapy targeting CD276 is 
currently being tested as a potential therapeutic target [117], however this single cell data 
contained single cells which had high methylation of CD276 and little corresponding 
expression, meaning these cells would be resistant to therapy. As a repercussion, therapy-
resistant cells would persist and consequently result in relapse. While this data focused on 
CD276, it highlights the principle of small sub-populations/single cells being non-responsive 
to certain therapies due to heterogeneity amongst the population. Additionally, the drop in 
methylation of the promoter region could potentially be used as a biomarker, as it appears to 
occur even in the primary tumour.  
 
Both CD276 and IGF2 showed significant decreases of methylation from normal adjacent 
tissue cells to carcinogenic cells. Similar to observations of focal hypermethylation and 
global trends, the cells which were from neoplastic tissues of the patients exhibited far more 
heterogeneity compared to cells from the matched colon healthy tissue.  
 
4.2.4 Limitations and Future Directions for Analysing Single Cell CRC Patient Data 
Multiple technical limitations were encountered while analysing this dataset, owing mostly to 
the nature of the data being obtained from single cell omics methods. The below section 
traverses these limitations, followed by suggestions for potential future directions that could 





One major limitation to my single cell data analysis was the inconsistent number of CpG sites 
in promoter regions of my target gene. CpG sites were filtered out which had a sequencing 
read depth of less than three, as I would have had little confidence in calling CpG sites with a 
lower sequencing read depth than this. Even a sequencing read depth of three is low 
compared to traditional bisulfite sequencing, however due to the nature of single cell 
sequencing it is not possible to get read depths matching those generated in bulk population 
sequencing, currently recommended to have a 30X coverage [118].  Allele specific and strand 
specific differences in methylation would also be difficult to detect, as the probability of 
covering both alleles and strands is unlikely for every single CpG genome wide. This was 
highlighted in my analyses as numerous CpG sites were absent in promoter regions of certain 
cells, but present in others. This resulted in a significantly smaller number of CpG sites 
within the promoter regions and consequently unequal ratios leading to skewed results. This 
created bias, as promoter regions with less CpG site data available was more likely to skew 
towards the extremes of no methylation, or complete methylation. One solution offered to 
this problem in single cell sequencing is to merge up to 10 homogeneous cells 
bioinformatically to reconstruct the methylome, however due to the heterogeneous nature of 
CRC, this solution cannot be applied. 
 
Another limitation of the data analysis was the small sample size per region. This may 
explain why commonly observed cancer DNAme phenomena were not reflected in my 
analysis. While an increase in sample size would potentially change this, in the special 
circumstances of single cell sequencing, the purpose is to identify rare sub-populations of 




One constraint which was encountered when comparing expression and methylation 
relationships between tissue regions, was the absence of normal adjacent colon tissue single 
cell expression data. This meant there was no control to compare the tumour region single 
cell expression to, to see if there was in fact a significant difference between them. The 
relationship between methylation and expression in some neoplastic cells was still explored 
where possible and informative, it just meant comparisons to the normal colon tissue was not 
viable. There were also more liver metastases cells with expression data available, explaining 
why often ML cells had expression of interest genes and other regions appeared not to. This 
over- and under- representation of tissue regions meant making any inferences about tissues 
over or under expressing certain genes was limited. The reason some cells were not able to 
have their transcriptomes captured is a result of the nature of scTrio sequencing. Capturing 
the genome, methylome and transcriptome from one single cell is an intricate task and 
capturing all three from each cell is not always possible. Despite this, the methylation data 
was still valuable, as it could still uncover potential biomarkers at these regions or influence 
the cancer genome in ways other than regulation of gene expression. 
 
The single cell data was also filtered to include only CpG sites for my analysis. This was 
done as my focus in my limited time frame was promoter regions of genes of interest, which 
are typically rich in CpG islands for regulation [119]. The potential role of non-CpG DNAme 
in cancers is becoming more appreciated, with numerous studies finding non-CpG DNAme 
implicated in the initiation and progression of cancer [120, 121]. On account of this, 
analysing single cell data with all methylated cytosines irrespective of their surrounding 




Due to time constraints as previously mentioned, only select cells from one patient was 
analysed in this thesis. However, there were 12 patients with hundreds of single cells 
available for analysis. My analysis also focused primarily on methylation data from these 
cells, however there was also genomic and transcriptomic data available. In future, analysing 
the entire dataset would provide a much greater picture of the interactions contributing to the 
disorderly cancer genome. As highlighted often throughout this thesis, DNAme has versatile 
effects on the genome, expanding beyond the scope of gene expression. Integrating data from 
the genome, transcriptome and methylome would exhibit interrelation of the three, enhancing 
the ability to identify cellular populations, cellular trajectories, and lineage tracing. Not only 
this, exploring the entire dataset would also unveil inter-individual heterogeneity between the 
12 CRC patients. All in all, the dataset used for my analysis provided an abundance of 
information with triple-omics data from a diverse range of patient samples at different stages, 
genders, and ages. It is a powerful dataset with copious domains that could be explored in the 
future, such as comparisons between individual’s primary tumours of different CRC stages, 
or liver metastases post-treatment to observe any different responses to chemotherapy.  
 
No cells from liver metastases post-treatment showed significant differences in methylation 
of the above genes compared to liver metastases cell pre-treatment. Research has shown the 
methylation status of certain genes render tumour cells drug resistant [122].Therefore, in 
future studies, considering methylomes of pre- and post- treatment liver metastases cells are 
available, examining the difference in methylation between ML and MP cells of these genes 
may be used clinically to identify any sub-populations present in the tumours which may be 




Single cell sequencing can be used to build upon principals already established from bulk 
sequencing. Bulk sequencing found the differences in methylation between normal tissues 
and tumours which led to my choice of interest genes to investigate for this thesis. Single cell 
sequencing allows for greater elucidation of these mechanisms and has relevant clinical 
applications.  
 
Chapter 5: Conclusion 
Overall, I was able to successfully optimise and implement the generation of single cell 
bisulfite sequencing libraries on the HT29 CRC cell line. Three single cell libraries were of 
high enough quality for sequencing, as well as other small cell amounts of 5 and 10 which are 
not attainable by traditional bulk population bisulfite sequencing methods. Furthermore, I 
was able to analyse publicly available scTrio-seq data to compare methylomes of single cells 
from a tumour and its matched normal colon tissue. This confirmed my hypothesis that a vast 
amount of heterogeneity would be observed between cells of CRC tumours, compared to 
normal tissue. This was seen at both a global and focal level, providing awareness into the 
amount of information lost when these cells are coalesced and sequenced as one. This section 
also highlighted the complex layers of gene expression, and that DNAme does not always 
infer expression. 
 
The implementation of this protocol has provided the base work for future experiments to be 
done possibly with patient samples.  While the bioinformatic analyses covered a broad range 
of pathways exploited in CRC and explored currently accepted biological models of cancer 




The initial plan of this project to address my hypothesis was to be achieved by optimising and 
implementing the scBS protocol, followed by analysis of my own data to see how greatly the 
cells methylomes varied from one another. Unfortunately, due to COVID-induced time 
restrictions, public single cell methylome data had to be used to address the second aim. 
Nonetheless, I was able to show that consistent with my hypothesis, heterogeneity both intra- 
and inter-tumourally in CRC cells is very prevalent and as such, single cell sequencing is a 
powerful tool in the field. 
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